Key result
Captopril reduced the venoconstrictor response to Ang I but had no significant effect on the response to [Pro(11)(D)-Ala(12)] Ang I.
Why the study?
Does [Pro11D-Ala12] Angiotensin I induce venoconstriction via a non-ACE pathway in patients with coronary heart disease?
RCT
Double-blind
Randomized
Does [Pro11D-Ala12] Angiotensin I induce venoconstriction via a non-ACE pathway in patients with coronary heart disease?
Answers are grounded in this paper and cite their sources.
A non-ACE pathway, likely involving chymase, is capable of generating Angiotensin II and inducing venoconstriction in human veins in vivo.
BACKGROUND: [Pro(11)(D)-Ala(12)] angiotensin I is an ACE-resistant substrate specific for chymase. We used this peptide to determine whether a functionally significant non-ACE angiotensin (Ang) II-generating pathway exists in human dorsal hand veins. METHODS AND RESULTS: Using a modified Aellig technique, we studied the response to Ang I and [Pro(11)(D)-Ala(12)] Ang I in dorsal hand veins in vivo in patients with coronary heart disease. We measured the venoconstrictor effect of each peptide given before and after a 6.25-mg oral dose of the ACE inhibitor captopril or matching placebo. Placebo or captopril was given in a double-blind, randomized fashion. Ang I induced a mean+/-SEM venoconstrictor response of 45+/-11%, 40+/-10%, 55+/-8%, and 4+/-4% before placebo, after placebo, before captopril, and after captopril, respectively. Hence, the response to Ang I was reproducible and was reduced significantly only after treatment with captopril (P=0.002). [Pro(11)(D)-Ala(12)] Ang I induced a mean venoconstrictor response of 42+/-9%, 49+/-9%, 48+/-10%, and 54+/-11% before placebo, after placebo, before captopril, and after captopril, respectively. Hence, captopril had no significant effect on the response to [Pro(11)(D)-Ala(12)] Ang I. CONCLUSIONS: We have demonstrated that [Pro(11)(D)-Ala(12)] Ang I is able to induce venoconstriction in humans in vivo. With this specific pharmacological probe, we have shown that a non-ACE pathway capable of generating Ang II exists in human veins in vivo and is potentially functionally important. This pathway is likely to involve the enzyme chymase.
No takes yet. Share an insight, caveat, or question.
McDonald et al. (2001) conducted an RCT in Coronary heart disease. Captopril vs. Placebo was evaluated on Venoconstrictor response to Ang I and [Pro(11)(D)-Ala(12)] Ang I (p=0.002). Captopril reduced the venoconstrictor response to Ang I but had no significant effect on the response to [Pro(11)(D)-Ala(12)] Ang I.
Synapse has enriched 10 related papers. Consider them for comparative context: